Abstract
The αvβ3 receptor, which are members of the group of the cellular adhesion molecules (CAM), are heterodimeric transmembrane glycoprotein receptors involved in processes such as cell-cell and cell-matrix adhesion, cell migration and signaling. Integrin αvβ3 receptor is expressed on almost all cells originating from the mesenchyme and seem to mediate several biological processes, including adhesion of osteoblasts to the bone matrix, migration of vascular smooth muscle cells, and angiogenesis. Many efforts were done in the last 10 years to individuate inhibitors for αvβ3 receptors, due to their involvement in important pathophysiological functions. In fact, selective αvβ3 antagonists offer new therapeutic opportunities for the treatment of several human pathologies like osteoporosis, restenosis and diseases involving neovascularization such as rheumatoid arthritis, tumor induced angiogenesis and metastasis. Purpose of this account is to summarize the recent developments in the field of non-peptidic αvβ3 antagonists.
Keywords: integrins, cellular adhesion molecules, crystal structure, vitronectin receptor, osteoblasts, carcinoma
Current Medicinal Chemistry
Title: Non Peptidic αvβ3 Antagonists: Recent Developments
Volume: 12 Issue: 1
Author(s): Barbara Cacciari and Giampiero Spalluto
Affiliation:
Keywords: integrins, cellular adhesion molecules, crystal structure, vitronectin receptor, osteoblasts, carcinoma
Abstract: The αvβ3 receptor, which are members of the group of the cellular adhesion molecules (CAM), are heterodimeric transmembrane glycoprotein receptors involved in processes such as cell-cell and cell-matrix adhesion, cell migration and signaling. Integrin αvβ3 receptor is expressed on almost all cells originating from the mesenchyme and seem to mediate several biological processes, including adhesion of osteoblasts to the bone matrix, migration of vascular smooth muscle cells, and angiogenesis. Many efforts were done in the last 10 years to individuate inhibitors for αvβ3 receptors, due to their involvement in important pathophysiological functions. In fact, selective αvβ3 antagonists offer new therapeutic opportunities for the treatment of several human pathologies like osteoporosis, restenosis and diseases involving neovascularization such as rheumatoid arthritis, tumor induced angiogenesis and metastasis. Purpose of this account is to summarize the recent developments in the field of non-peptidic αvβ3 antagonists.
Export Options
About this article
Cite this article as:
Cacciari Barbara and Spalluto Giampiero, Non Peptidic αvβ3 Antagonists: Recent Developments, Current Medicinal Chemistry 2005; 12 (1) . https://dx.doi.org/10.2174/0929867053363522
DOI https://dx.doi.org/10.2174/0929867053363522 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines: A Potential Therapeutic Target to Suppress Autoimmune Arthritis
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Activated Synovial Macrophages as Targets for Osteoarthritis Drug Therapy
Current Drug Targets The Emerging Role of Exosomal Non-coding RNAs in Musculoskeletal Diseases
Current Pharmaceutical Design Combination Therapy in Fibromyalgia
Current Pharmaceutical Design Editorial [Hot Topic: Pathophysiology and Current Therapeutics of Inflammatory Diseases (Guest Editor: Fadia R. Homaidan)]
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?
Current Medicinal Chemistry Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design Modulating Poly (ADP-Ribose) Polymerase Activity: Potential for the Prevention and Therapy of Pathogenic Situations Involving DNA Damage and Oxidative Stress
Current Pharmaceutical Biotechnology Editorial [Hot topic: Immunological Regulation of the Central Nervous System: From Physiological to Pathological Processes (Guest Editor: Oscar Gonzalez-Perez)]
Current Immunology Reviews (Discontinued) Pharmacokinetic Profile of A New Diclofenac Prodrug without Gastroulcerogenic Effect
Drug Metabolism Letters New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Salivary Total Sialic Acid Levels Increase in Breast Cancer Patients: A Preliminary Study
Medicinal Chemistry Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Anti-Cancer Agents in Medicinal Chemistry The Role of Cytokines in Sleep Regulation
Current Pharmaceutical Design The Role of Wrist Fusion and Wrist Arthroplasty in Rheumatoid Arthritis
Current Rheumatology Reviews Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms
Current Pharmacogenomics The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets